CTSO - Company ID 0001175151
The table below shows Cytosorbents Corp's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.38M | -$14.43M | -$21.66M | -$28.23M | -$14.01M | -$5.61M |
| Capital expenditure | $164.00K | $284.00K | $538.12K | $6.09M | $3.64M | $708.39K |
| Investing cash flow | -$415.00K | -$669.00K | -$936.24K | -$6.46M | -$4.28M | -$1.68M |
| Dividends paid | - | - | - |
Cytosorbents Corp reported operating cash flow of -$12.38M for fiscal year 2025. That is up 14.2% from -$14.43M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$6.73M (FY 2016) to -$12.38M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $9.31M | $9.33M | $14.47M | $4.96M | $715.20K | $66.35M |